Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05281237 · ClinicalTrials.gov registry record · NA
Avecure Flexible Microwave Ablation Probe For Lung Nodules
A NA study of Lung Cancer and Lung Cancer Stage II, sponsored by Beth Israel Deaconess Medical Center.
- Recruiting
- Registry status
- NA
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT05281237: Recruiting NA study of Lung Cancer and Lung Cancer Stage II, sponsored by Beth Israel Deaconess Medical Center.
NCT05281237 is a NA study of Lung Cancer and Lung Cancer Stage II that is actively recruiting participants, run by Beth Israel Deaconess Medical Center. The registered enrollment target is 10 participants, below the 936-participant average among 409 other Lung Cancer trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05281237, a NA study of Lung Cancer and Lung Cancer Stage II, is actively recruiting participants, sponsored by Beth Israel Deaconess Medical Center.
- RECRUITING
- Registry status
- NA
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
This research study to determine the effectiveness of the AveCure Flexible Microwave Ablation Probe to destroy cancerous lung nodules up to 3 c m in size. This research study involves microwave ablation (MWA)
Primary Outcome
Feasibility of performing the procedure as planned in the enrolled patients. At least 9/10 of the planned ablations (90%) can be performed bronchoscopically according to the established protocol.
Conditions Studied
Interventions
- DEVICE AveCure 16 Gauge Flexible Microwave Ablation Probe
Study Locations (1)
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2022-06-01 |
| Est. Completion | 2027-06-30 |
| Phase | NA |
What NCT05281237 shows while recruiting
NCT05281237 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 936-participant average among 409 other Lung Cancer trials with a reported enrollment target (99% lower).
The record links to 6 conditions, with Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which AveCure 16 Gauge Flexible Microwave Ablation Probe is the first listed.
NCT05281237 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05281237 about?
NCT05281237 is a clinical study titled "Avecure Flexible Microwave Ablation Probe For Lung Nodules". This research study to determine the effectiveness of the AveCure Flexible Microwave Ablation Probe to destroy cancerous lung nodules up to 3 c m in size. This research study involves microwave ablation (MWA)
What is the current status of trial NCT05281237?
This trial is currently recruiting. It is a NA study. The enrollment target is 10 participants. The study started on 2022-06-01. Estimated completion is 2027-06-30.
What conditions does trial NCT05281237 study?
This clinical trial studies the following conditions: Lung Cancer, Lung Cancer Stage II, Stage II Lung Cancer, Lung Cancer Stage I, Stage I Lung Cancer.
What interventions are being tested in trial NCT05281237?
The interventions under investigation include: AveCure 16 Gauge Flexible Microwave Ablation Probe (DEVICE).
Who is sponsoring clinical trial NCT05281237?
This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05281237 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05281237's enrollment target sits among peer trials
10 393rd of 409 higher than 14 of 409 other Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Lung B.A.S.E.S. 4 Life Mobile Low-dose Computed Tomography (LDCT) Screening: Ages 40-54
RECRUITING · NA
-
Lung Cancer Screening in High-risk Black Individuals
RECRUITING · NA
-
A Patient and Provider Intervention to Address Health Disparities in Lung Cancer Screening
RECRUITING · NA
-
Exercise as Maintenance Therapy in Advanced Lung Cancer
RECRUITING · NA
-
Improving Care for Rural Patients With Solid Tumors
RECRUITING · NA
-
Stereotactic Magnetic Resonance Guided Radiation Therapy
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI